ALSO READZydus Cadila gets final USFDA nod for hypertension drug Zydus Cadila receives USFDA approval to market blood pressure drug Zydus Cadila gets USFDA nod to market anti-dementia drug Zydus Cadila gets USFDA nod for drug used to reduce risk of strokes USFDA approves Zydus Cadila drugs for brain tumour, hypertension
Cadila Healthcare today said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine and Olmesartan Medoxomil tablets.
The nod by US Food and Drug Administration (USFDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a BSE filing.
"The drug is indicated for the treatment of hypertension, alone or with other anti-hypertensive agents to lower blood pressure and will be manufactured at the group's formulations manufacturing facility at Pharma SEZ Ahmedabad," Cadila Healthcare added.
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)